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Background: Type 2 diabetes mellitus is the most common form of diabetes. Metformin is a ﬁrst-line
drug for its treatment. In Mexico, there are 34 generic formulations of metformin, so brand-generic
substitutions and generic-generic substitutions are a common practice. Generic products are compared
only with their brand-name equivalents and not with the same product made by other manufacturers.
Objective: Our aim was to establish whether 2 generic formulations of 500 mg metformin available on
the Mexican market fulﬁll the criteria for interchangeability.
Methods: This single-dose, randomized-sequence, open-label, 3-period crossover study was conducted
in 12 healthy subjects in compliance with the Declaration of Helsinki and International Conference on
Harmonization guidelines. A validated HPLC procedure coupled with a spectrum mass detector were
used to analyze the metformin concentration in plasma samples. All pharmacokinetic analyses were
performed using WinNonlin Professional Software version 6.3 (Pharsight Corporation, Sunnyvale,
California).
Results: Twelve healthy Mexican volunteers were enrolled in the study. Their mean age was 24.33 years
and mean weight was 62.54 kg. The mean body mass index was 23.02. The values obtained for the test
and reference formulations were: Cmax 1163.5 (295.2) ng/mL for treatment A, 1184.6 (215.0) ng/mL for
treatment B, and 1167.8 (176.8) ng/mL for treatment C. AUC0–t was 6240.7 (1629.4) ng/mL/h for treatment
A, 6433.7 (1249.8) ng/mL/h for treatment B, and 6567.1 (1145.5) ng/mL/h for treatment C. AUC0–1 was
6837.3 (1618.5) ng/mL/h for treatment A, 6911.8 (1178.4) ng/mL/h for treatment B, and 7178.6 (1086.8)
ng/mL/h for treatment C.
Conclusions: The test formulation 500-mg metformin tablets were bioequivalent to the reference
formulation and to each other, according to the general laws of health care in Mexico.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Diabetes mellitus is a complex chronic illness requiring con-
tinuous medical care with multifactorial risk reduction strategies
beyond glycemic control.1 The worldwide prevalence of diabetes
mellitus is currently estimated to be around 180 million and the
World Health Organization predicts this number to double by
2030.2 Type 2 diabetes mellitus is the most common form of theInc. This is an open access article u
añas, Departamento de Farm-
rsidad Autónoma de Nuevo
Monterrey, Nuevo León, CP
añas).disease (affecting 90%–95% of persons with diabetes) and is
characterized by an underlying insufﬁciency of insulin.3,4
Metformin is an orally administered antidiabetic drug from the
biguanide class. It is recommended as a ﬁrst-line drug for the
treatment of type 2 diabetes mellitus.5
Metformin acts in the presence of insulin to increase glucose
use and reduce glucose production, thereby counteracting insulin
resistance. The effects of metformin include increased glucose
uptake, oxidation and glycogenesis by muscle, increased glucose
metabolism, and reduced hepatic gluconeogenesis.4 Metformin is
mainly absorbed in the small intestine and has an oral bioavail-
ability of 60% under fasting conditions. Its plasma protein binding
is negligible, and it is not metabolized by the liver. Metformin is
90% excreted unchanged in urine.6nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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brand-to-generic substitution and generic-generic substitutions
are a common practice.7,8 It is important to keep in mind that
generic products are only compared with their brand-name
products and not with the same product made by other
manufacturers.
Some studies9–11 have warned about the lack of pharmacoki-
netic bioequivalence among generic drugs in the postmarketing
setting. Therefore, based on these considerations, the aim of our
work was to establish whether 2 generic formulations of 500 mg
metformin available on the Mexican market fulﬁll the criteria for
interchangeability.Subjects and Methods
Materials
Metformin chlorhydrate USP was used for the study. HPLC-
grade acetonitrile was purchased from Tedia High Purity Solvents
(Fairﬁeld, Ohio), HPLC-grade methanol and formic acid were
purchased from Fermont (Monterrey, Nuevo León, Mexico). Deion-
ized water was purchased from Laboratorios Monterrey (Monter-
rey, Nuevo León, Mexico).
Products evaluated
Reference A tested 500-mg Dabex tablets (Merck S.A. de C.V.
Naucalpan de Juárez, Estado de México, México). Batch M33801,
expires June 2017). Test B utilized 500-mg Pre-Dial tablets (Labo-
ratorios Silanes S.A. de C.V. Toluca Estado de México, México).
Batch 13LI07VI, expires November 2015. Test C utilized 500-mg
Dimefor tablets (Siegfried Rhein Querétaro, Qro. México). Batch
310507, expires September 2015.
Study subjects
Twelve healthy adult (male and female) Mexican volunteers
participated in the study. All were in good health based on their
medical histories, complete physical examination, vital signs (eg,
heart rate, systolic and diastolic blood pressure, and body temper-
ature), and routine laboratory tests performed before and after the
study (eg, complete blood count, blood chemistry, urinalysis,
pregnancy test for women, renal and liver function tests, antibody
testing for HIV, hepatitis B surface antigen, and hepatitis C virus).
None had a history of any allergy to metformin and related
compounds. Subjects did not receive any other medication during
the study. All volunteers abstained from any xantine-containing
food or beverages or alcoholic products for 48 hours before dosing
and throughout the sampling schedule during each period.
Study design
The study was conducted in the Departamento de Farmacología
y Toxicología, Facultad de Medicina, Universidad Autónoma de
Nuevo León.
This is a single-dose, randomized-sequence, open-label,
3-period crossover study that was carried out under fasting
conditions with a 1-week washout period.
Subjects were admitted and housed in our clinical pharmacol-
ogy unit for 12 hours before the dose and were discharged 24
hours after the dose during each period. A single 500-mg tablet of
the formulations was administered with 250 mL water after an
overnight fast. A total of 15 venous blood samples (5 mL each)
were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4,6, 8, 12, and 16 hours. Serum was separated by centrifugation at
12,500 rpm for 10 minutes, and stored at –401C until analysis.
A standardized breakfast and lunch were given at 4 and 8 hours,
respectively, after medication administration.
Ethical considerations
The study protocol and the informed consent form were
approved on May 6, 2014, by our institutional ethics and research
committee (study No. FA14-001) and the study was conducted in
accordance with the principles of the Declaration of Helsinki12 and
its amendments, the International Conference on Harmonization
Guidelines for Good Clinical Practice,13 and the general laws of
health care in Mexico.14 The order of treatment sequence (refer-
ence or test drugs) was randomized using Excel (version 2010,
2010, Microsoft Corp, Redmond, Washington).
Bioanalytic methods
The sample preparation process was accomplished by protein
precipitation using acetonitrile. A 200-μL aliquot of each plasma
sample was transferred to a polypropylene tube (Eppendorf,
Hamburg, Germany), and 1000 μL acetonitrile was added. After
brief vortex mixing, the tubes were centrifuged at 12,500 rpm for
10 minutes. Then the supernatants were evaporated to dryness
under a nitrogen stream at 60ºC, reconstituted with 400 μL assay
mobile phase, vortexed for 2 minutes, and then centrifuged at
12,500 rpm for 4 minutes. The supernatant was transferred to a
vial with a ﬂat bottom glass insert.
Plasma concentrations of metformin were determined using
HPLC-MS/MS using an Agilent Technologies (Palo Alto, California)
Model 1100 series instrument equipped with a degassing unit, a
high pressure binary pump, an autosampler, and a mass spec-
trometer detector (6410 B; Agilent Technologies), using a method
based on that published by Kandhwal et al15 and Harahap et al.16
Separations were performed on a Zorbax HILIC Plus Rapid Reso-
lution 4.6  100 mm, 3.5 μm column (Agilent Technologies), and
eluted with a mobile phase consisting of 2.65 mM acetonitrile and
formic acid solution (40%/60% v/v). The eluate was ﬁltered through
a 0.45 μm pore size cellulose membrane. The chromatographic
separation was performed isocratically at 211C at a ﬂow rate of
0.8 mL/min.
Tolerability
Tolerability was determined by clinical assessment and mon-
itoring vital signs (eg, blood pressure, heart rate, and body
temperature) at baseline, 3 times during the study, and at the
end of the periods. Laboratory analyses were also performed
before and after the study. In addition, subjects were required to
report to the investigators any adverse effects that occurred at any
time during the study, including during the washout period.
Pharmacokinetic analysis
The following pharmacokinetic values for each subject and for
each treatment were determined: Cmax, Tmax, AUC0–t, AUC0–1, and
T1/2. AUC0–t was calculated using the linear trapezoidal rule17 and
AUC0–1 was calculated as the sum of AUC0–t and the extrapolated
area under the concentration time curve (Clast/elimination rate
constant [Ke]). Cmax and Tmax were obtained directly from the
original data set and t1/2 was calculated as ln2/Ke. Ke was obtained
by linear regression from the best-ﬁt slope of the terminal log-
linear decay in plasma concentrations versus time proﬁle. All
pharmacokinetic analyses were performed using WinNonlin
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Figure 1. Comparison of limit of quantiﬁcation versus blank (plasma).
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vale, California).Table I
Mean plasma concentration for treatment A (reference), treatment B (test), and
treatment C (test).
Time
(h)
Treatment A (reference)
(ng/mL)
Treatment B (test)
(ng/mL)
Treatment C (test)
(ng/mL)Statistical analysis
All statistical analyses were carried out using SPSS software
version 13.0 (IBM-SPSS Inc, Armonk, New York).
Using a noncompartmental analysis , ANOVA was performed to
test the signiﬁcant differences between formulations with the
logarithmically transformed values of AUC0–t, AUC0–1, and Cmax.18
In addition, Schuirmann’s 2 1-sided t test procedure was used to
assess the bioequivalence of the pharmacokinetic characteristics of
the 2 medications.14
As recommended by Food and Drug Administration guidance,
data were log transformed. Using logarithmic transformation, the
general linear statistical model employed in the analysis of
bioequivalence data allows inferences about the difference
between the 2 means on the log scale, which can then be
retransformed into inferences about the ratio of the 2 averages
(means or medians) on the original scale. Logarithmic trans-
formation thus achieves a general comparison based on the ratio
rather than the differences.19 The formulations were considered
bioequivalent when the logarithmically transformed values of
Cmax, AUC0–t, and AUC0–1 were within the predetermined equiv-
alence range of 80% to 125% with a 90% CI. Differences were
considered signiﬁcant at P o 0.05.0.00 Lower than LOQ Lower than LOQ Lower than LOQ
0.25 Lower than LOQ Lower than LOQ Lower than LOQ
0.50 346.66 316.62 226.48
0.75 611.80 591.12 515.23
1.00 805.59 769.42 707.65
1.50 883.94 897.81 902.75
2.00 963.10 1034.39 993.84
2.50 1005.47 1067.74 1036.33
3.00 1022.89 1088.17 1057.12
3.50 1023.70 1073.87 1069.77
4.00 1022.28 1019.25 1048.18
6.00 553.60 562.80 603.43
8.00 302.43 297.76 334.99
12.00 Lower than LOQ 80.60 90.44
16.00 Lower than LOQ Lower than LOQ Lower than LOQ
LOQ ¼ limit of quantiﬁcation.Results
Subjects
Twelve healthy Mexican volunteers (5 men and 7 women) were
enrolled and all completed all periods of the study. Their mean
(SD) age and weight was 24.33 (6.34) years (range ¼ 19–38 years),
and 62.54 (9.34) kg (range ¼ 48.2–82.0 kg), respectively. The
mean body mass index was 23.02 (range ¼ 18.59–26.50). A power
analysis (value expected of at least 1 – β ¼ 0.8) determined that
the power of the ANOVA was 4 0.8 at a 90% CI, indicating that the
number of subjects enrolled in the study was sufﬁcient.Method validation
This method was developed and validated for speciﬁcity,
sensitivity, linearity, matrix effect, precision, accuracy, and stability
in our laboratory under NOM-177-SSA1-2013 speciﬁcations. In this
regard, metformin quantiﬁcation was not interfered with by
acetaminophen, aspirin, caffeine, diclofenac, ibuprofen, heparin,
loratadine, or naproxen.
The retention time for metformin was found to be 1.78
minutes. The relationship between concentration and peak area
ratio was found to be linear within the range of 78.88 to 2524.25
ng/mL (r2 4 0.991). The limit of quantiﬁcation was 78.88 ng/mL.
Accuracy from control samples at 236.65, 473.30, and 1893.19 ng/
mL concentrations was 14.37%, 3.94%, and 8.81%, respectively. The
intra-assay coefﬁcient of variation was 2.20%, 4.00%, and 3.07%,
respectively; and the interassay coefﬁcient of variation was 0.18%,
0.63%, and 2.59%, respectively. No signiﬁcant degradation of
metformin during freezing and thawing cycles, short and long
storage, or processing conditions was noted. Absence of interfer-
ing components was accepted where the response is o 20% of
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from endogenous compounds, anticoagulants, or possible drugs
concomitantly administered (eg, diclofenac, aspirin, aceta-
minophen, naproxen, loratadine, and caffeine) was observed.
Comparison of Limit of quantiﬁcation versus blank plasma are
shown in Figure 1.
Plasma pharmacokinetic analysis
The mean plasma concentration for all volunteers is shown in
Table I.
The plot of mean plasma concentration (N ¼ 12) versus time
for all volunteers is shown in Figure 2 and 3. There were no
signiﬁcant between-group differences for any of the pharmacoki-
netic parameters.Table II
Pharmacokinetic parameters of metformin for treatment A (reference) versus
treatment B (test).
Pharmacoki-
netic parameter
Treatment B:
treatment A (%)
95% CI P value Power
Ln(Cmax) 102.86 95.12–111.24 0.00017 0.99772
Ln(AUC0–t) 104.46 95.98–113.68 0.00076 0.99476
Ln(AUC0–1) 103.48 95.50–112.13 0.00033 0.99685
Ln ¼ natural logarithm.Metformin was absorbed rapidly, with a mean (SD) Tmax of 3.0
(1.0) hours for treatment A (reference), 2.8 (0.78) hours for treat-
ment B (test), and 3.0 (0.87) hours for treatment C (test).
The mean (SD) Cmax was 1163.5 (295.2 ng/mL) for treatment A
(reference), 1184.6 (215.0) ng/mL for treatment B (test), and 1167.8
(176.8) ng/mL for treatment C (test).
The mean (SD) AUC0–t was 6240.7 (1629.4) ng/mL/h for treat-
ment A (reference), 6433.7 (1249.8) ng/mL/h for treatment B (test),
and 6567.1 (1145.5) ng/mL/h for treatment C (test).
The mean (SD) AUC0–1 was 6837.3 (1618.5) ng/mL/h for treat-
ment A (reference), 6911.8 (1178.4) ng/mL/h for treatment B (test),
and 7178.6 (1086.8) ng/mL/h for treatment C (test).
The mean (SD) t½ (h) 2.34 (0.34) hours for treatment A
(reference), 2.38 (0.21) hours for treatment B (test), and 2.42
(0.31) hours for treatment C (test).Table III
Pharmacokinetic parameters of metformin for treatment A (reference) versus
treatment C (test).
Pharmacoki-
netic parameter
Treatment C:
treatment A (%)
90% CI P value Power
Ln(Cmax) 101.94 94.27–110.24 0.00010 0.99772
Ln(AUC0–t) 106.94 98.26–116.38 0.00234 0.99476
Ln(AUC0–1) 106.78 98.24–116.06 0.00207 0.99533
Ln ¼ natural logarithm.
Table IV
Pharmacokinetic parameters of metformin for treatment B (test) versus treatment
C (test).
Pharmacoki-
netic parameter
Treatment C:
treatment B (%)
90% CI P value Power
Ln(Cmax) 99.104 91.65–107.17 0.000039 0.99772
Ln(AUC0–t) 102.376 94.07–111.41 0.000266 0.99476
Ln(AUC0–1) 103.186 95.23–111.81 0.000285 0.99685
Ln ¼ natural logarithm.
Table VI
P values for variations between test formulations and reference metformin in
healthy adult Mexican volunteers, based on formulation, period, and sequence
using ANOVA.
Source of variation Ln(Cmax) Ln(AUC0–t) Ln(AUC0–1)
Formulation 0.8185 0.3987 0.4445
Sequence 0.6278 0.5878 0.6226
Period 0.4332 0.2413 0.2324
Ln ¼ natural logarithm.
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AUC0–t, AUC0–1, and Cmax are shown on Tables II, III, IV, and V. A
90% CI was applied.
ANOVA for the crossover design was used to assess
the formulation, period, and sequence effects on the plasma
pharmacokinetic parameters (Table VI). The parameters
were not signiﬁcantly different in terms of variation in
formulation.Discussion
The pharmacokinetic parameters obtained in this study with
the test and reference formulations were not signiﬁcantly differ-
ent, which reﬂects the comparable pharmacokinetic characteristics
of the 3 formulations. These results demonstrate that the test
formulations are bioequivalent to the reference product, as well as
to each other.
Metformin is not metabolized and is excreted unchanged in the
urine; active tubular secretion in the kidneys is the principal route
of metformin elimination. The drug is widely distributed into body
tissues by organic cation transporters. Genetic
polymorphisms in these transporter genes are also likely to
have a direct inﬂuence on metformin pharmacokinetics and
variability in drug responses.20
The pharmacokinetic parameters; that is, Cmax (1171.96
[7227.68] ng/mL) and AUC0–t (6413 [71325.17] ng/mL/h), are
not different from data reported by Santos et al6 in healthy
Mexican volunteers (Cmax 1390 [7440] ng/mL and AUC0–t 7590
[73170] ng/mL/h).
A study of 500 mg metformin in Chinese volunteers,21 Cmax
1128 [7160] ng/mL, AUC0–t 8626 [71800 ng/mL/h], and t½ of 3.5
[71.3] h were different from this study. The difference in t½ could
be a reason for a bigger AUC.
The use of pharmacokinetic bioequivalence to demonstrate that
generic formulations are bioequivalent is currently a matter of
discussion. Several studies have shown that generic formulations
are not bioequivalent to the reference product in the postmarket-
ing setting; however, 1 generic formulation had not been com-
pared against another generic formulation.
Some studies10 are limited by small simple size, but our study
had an adequate number of healthy volunteers, and the power ofTable V
Pharmacokinetic parameters of metformin for treatment C (test) versus treatment
B (test).
Pharmacoki-
netic parameter
Treatment B:
treatment C (%)
90% CI P value Power
Ln(Cmax) 100.90 93.31–109.12 0.000039 0.99772
Ln(AUC0–t) 97.68 89.76–106.30 0.000266 0.99476
Ln(AUC0–1) 96.91 89.44–105.01 0.000285 0.99685
Ln ¼ natural logarithm.the statistical analysis is appropriate to establish bioequivalence
among the three formulations of metformin.Conclusions
The HPLC-MS/MS detection used for metformin quantiﬁcation
provided the appropriate sensitivity, speciﬁcity, and high sample
throughput required for pharmacokinetic studies.
Our study established that the test formulation 500-mg met-
formin tablets were bioequivalent to the reference formulation
and to each other, according to the general laws of health care in
Mexico in this population of healthy adult Mexican volunteers;
therefore, all treatments can be safely substituted.Acknowledgments
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